登录 | 注册    关注公众号  
微信公众号
搜索
 > 【APRIL】

APRIL信息

英文名称:Tumor necrosis factor ligand superfamily member 13
中文名称:肿瘤坏死因子配体超家族成员13
靶点别称:Tumor Necrosis Factor Ligand 7B,CD256 Antigen,TNLG7B,CD256,TNF- and APOL-related leukocyte expressed ligand 2,TNFSF13,TNF-related death ligand 1,ZTNF2,TALL-2,APRIL,Tumor necrosis factor ligand superfamily member 13,TNF Superfamily Member 13,Tumor Necrosis Factor (Ligand) Superfamily, Member 13,TRDL-1,TALL2,Tumor Necrosis Factor Superfamily Member 13,Tumor Necrosis Factor-Like Protein ZTNF2,UNQ383/PRO715,A Proliferation-Inducing Ligand,Tumor Necrosis Factor-Related Death Ligand-1
上市药物数量:1
临床药物数量:8
最高研发阶段:批准上市

APRIL产品列表

 
评论(4)
APL-H52D1|Human APRIL / TNFSF13 Protein, His,Flag Tag, active trimer (MALS verified)
  1. 156XXXXXXX9
  2. 1人赞
  3. 我们之前使用某公司的April试剂盒检测血清基质中April浓度,但由于试剂盒带的参比品问题,导致检测结果均低于定量下限,后采购ACRO公司的April蛋白作为标准品检测April,现在结果均非常理想,不同批次产品平行性好。
  4. 2021-08-18
APL-H5268|Human APRIL / TNFSF13 Protein, Fc Tag, active trimer (MALS verified)
  1. 156XXXXXXX9
  2. 0人赞
  3. 使用APRIL作为对照品,检测人血清中APRIL的浓度。原理为ELISA原理。浓度高,性质稳定,批间差异小,现方法已转移至美国进行申报临床项目中使用,希望可以得到满意的结果。
  4. 2022-08-30
APL-H52D1|Human APRIL / TNFSF13 Protein, His,Flag Tag, active trimer (MALS verified)
  1. 188XXXXXXX5
  2. 0人赞
  3. 采购该蛋白APL-H52D1,用于与TNFSF13的互作受体蛋白的ELISA检测,基于阳性对照抗体的阻断ELISA QC实验结果符合预期,可以用于筛选阻断型抗体。
  4. 2021-11-21
 

APRIL 分子别名

APRIL,TNFSF13,TALL-2,TRDL-1,CD256,TALL2,ZTNF2

APRIL 分子背景

APRIL(a proliferation-inducing ligand) is also known as Tumor necrosis factor ligand superfamily member 13, TALL-2, TRDL-1, CD256, TNFFSF 13, cytokine that binds to TNFRSF13B/TACI and to TNFRSF17/BCMA. APRIL is a cytokine of the tumor necrosis factor family associated mainly with hematologic malignancies. The closely related TNF family ligands B cell activation factor (BAFF) and a proliferation-inducing ligand (APRIL) serve in the generation and maintenance of mature B-lymphocytes. Both BAFF and APRIL assemble as homotrimers that bind and activate several receptors that they partially share. BAFF-APRIL heteromers of different stoichiometries have distinct receptor-binding properties and activities. In addition, expression of APRIL was regulated by miR-145 in GC cells.

APRIL 前沿进展

APRIL上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Telitacicept 泰它西普 RCT-18; RC-18; RCT18; RC18 批准上市 荣昌生物制药(烟台)股份有限公司 泰爱 Mainland China 系统性红斑狼疮 RemeGen Co Ltd 2021-03-09 重症肌无力, 复发-缓解型多发性硬化, 免疫球蛋白a肾病, 类风湿关节炎, Sjtoegren综合征, 多发性硬化, 视神经脊髓炎, 系统性红斑狼疮 详情

APRIL临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
AUR-200 AUR-200 临床一期 Thunderbolt Pharma Inc 自身免疫疾病 详情
Anti-BCMA CAR T-cell therapy (Huazhong University of Science and Technology) 临床阶段不明 华中科技大学 多发性骨髓瘤 详情
APRIL CAR-T Cell therapy (Yake Biotechnology) 临床一期 上海雅科生物科技有限公司 多发性骨髓瘤 详情
RO-7297089 RO-7297089; AFM-26; RG-6296 基因泰克 详情
Sibeprenlimab VIS-649 临床一期 Visterra 免疫球蛋白a肾病 详情
BION-1301 BION-1301 Aduro Biotech 详情
anti-TriPRIL CAR T-cell therapy(Massachusetts General Hospital) 临床一期 Massachusetts General Hospital 多发性骨髓瘤 详情
Atacicept TACI-Ig 临床二期 Zymogenetics 免疫球蛋白a肾病, 类风湿关节炎, 多发性硬化, 视神经炎, 狼疮肾炎, 系统性红斑狼疮 详情

消息提示

请输入您的联系方式,再点击提交!

确定